We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Epigenetic Variation May Be Responsible for Hereditary Disorders

By LabMedica International staff writers
Posted on 07 Jun 2018
Genomics researchers have suggested that some hereditary disorders are caused by epigenetic variation that modifies gene expression rather than by traditional mutation that changes the sequence of DNA bases.

Certain human traits such as neurodevelopmental disorders (NDs) and congenital anomalies (CAs) are believed to be primarily genetic in origin. More...
However, even after whole-genome sequencing (WGS), a substantial fraction of such disorders remain unexplained.

To solve this mystery, investigators at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) proposed that some cases of ND–CA were likely caused by aberrant DNA methylation leading to epigenetic variation (epivariation) that disrupted genome function.

To test this theory, the investigators compared DNA methylation profiles from 489 individuals with ND–CAs to 1534 samples from control subjects. In the May 25, 2018, online edition of the journal Nature Communications, they reported that epivariations frequently occurred in the human genome. De novo epivariations were significantly enriched in ND-CA cases, while RNAseq analysis showed that epivariations often had an impact on gene expression comparable to loss-of-function mutations.

"Our study suggests that these epigenetic mutations are a significant contributor to human disease," said senior author Dr. Andrew Sharp, associate professor of genetic and genomic sciences at the Icahn School of Medicine. "These findings can open up a whole new world in what we know about disease and genetic profiling. Investigating DNA methylation when profiling genomes for disease mutations could help us uncover causative defects in congenital and neurodevelopmental diseases that have eluded us for years."

Related Links:
Icahn School of Medicine at Mount Sinai


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.